Clive Meanwell gives way to new CEO as activist investor Alex Denner shakes up The Medicines Company
Alex Denner has made his first public move at The Medicines Company since consolidating power on the board — and it’s a big one.
Clive Meanwell passing the CEO role and his board seat to Merck vet Mark Timney, leaving a position he’s occupied for the better part of the company’s 22-year history.
He’s not out entirely. In the newly-created role of chief innovation officer, he is tasked with supporting the ongoing development of inclisiran — the biotech’s experimental LDL-lowering RNAi therapy in-licensed from Alnylam.
Basic subscription required
Unlock this story instantly and join 55,200+ biopharma pros reading Endpoints daily — and it's free.